A5008149414- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Prostate Cancer Treatment and Research
- Proteoglycans and glycosaminoglycans research
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- Glycosylation and Glycoproteins Research
- Biosimilars and Bioanalytical Methods
- Immune Cell Function and Interaction
- Safe Handling of Antineoplastic Drugs
- Colorectal Cancer Treatments and Studies
- Click Chemistry and Applications
- Lanthanide and Transition Metal Complexes
- Cancer Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Cell Adhesion Molecules Research
- Ovarian cancer diagnosis and treatment
- Cancer therapeutics and mechanisms
- Lung Cancer Research Studies
- Research on Leishmaniasis Studies
- Virus-based gene therapy research
Istituto Oncologico Veneto
2018-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2018-2023
University of Padua
2014-2017
Prostate cancer (PCa) has become the most common among males in Europe and USA. Adoptive immunotherapy appears a promising strategy to control advanced stages of disease by specifically targeting tumor, particular through chimeric antigen receptor T (CAR-T) cell therapy. Despite advancements CAR-T technology treatment hematological malignancies, solid tumors still represent challenge. To overcome current limits, other cellular effectors than lymphocytes are under study as possible candidates...
Cytokine-Induced Killer (CIK) cells share several functional and phenotypical properties of both T natural killer (NK) cells. They represent an attractive approach for cell-based immunotherapy, as they do not require antigen-specific priming tumor cell recognition, can be rapidly expanded in vitro. Their relevant expression FcγRIIIa (CD16a) exploited combination with clinical-grade monoclonal antibodies (mAbs) to redirect their lytic activity manner. Here, we report the efficacy this...
We report the synthesis of three optical probes (Eu3+⊂1, Eu3+⊂2, and Eu3+⊂3) having a luminescent Eu complex (signaling unit) bonded in different positions to folic acid (FA), folate receptor (FR) targeting unit. The structures two regioisomers Eu3+⊂1 Eu3+⊂2 were assigned by mass spectrometric experiments. properties stability these assessed phosphate-buffered saline, cell culture medium, rat serum, cellular lysate, results indicated that they are chemically photophysically stable....
Abstract One of the main goals vaccine research is development adjuvants that can enhance immune responses and are both safe biocompatible. We explored application natural polymer hyaluronan (HA) as a promising immunological adjuvant for protein-based vaccines. Chemical conjugation HA to antigens strongly increased their immunogenicity, reduced booster requirements, allowed antigen dose sparing. HA-based bioconjugates stimulated robust long-lasting humoral without addition other...
// Anastasia De Luca 1 , Dante Rotili 2 Debora Carpanese 3 Alessia Lenoci Laura Calderan 4 Manuel Scimeca 5, 6 Antonello Mai 2, 7 Elena Bonanno Antonio Rosato 3, 8 Cristina Geroni 9 Luigi Quintieri Anna Maria Caccuri 1, 10 The NAST Centre for Nanoscience & Nanotechnology Innovative Instrumentation, University of Tor Vergata, 00133 Rome, Italy Department Drug Chemistry and Technologies, "Sapienza" University, 00185 Surgery, Oncology Gastroenterology, Padova, 35128 Pharmaceutical...
While interferon alpha (IFNα) is used in several viral and cancer contexts, its efficacy against ovarian (OC) far from being incontrovertibly demonstrated and, more importantly, hindered by heavy systemic side effects. To overcome these issues, here we propose a strategy that allows targeted delivery of the cytokine, conjugating IFNα2a with an aldehyde-modified form hyaluronic acid (HA). The resulting HA-IFNα2a bioconjugate was biochemically biologically characterized. conjugation HA did not...
Management of ovarian cancer still requires improvements in therapeutic options. A drug delivery strategy was tested that allows specific targeting tumor cells combination with a controlled release cytotoxic molecule. To this aim, the efficacy loco-regional intraperitoneal treatment bioconjugate (ONCOFID-S) derived by chemical linking SN-38, active metabolite irinotecan (CPT-11), to hyaluronan assessed mouse model carcinomatosis. In vitro, selectively interacted through CD44 receptor,...
New integrin-selective molecules suitable for therapeutic or imaging purposes are currently of interest in development effective personalized medical platforms. RGDechi is a bifunctional peptide selective integrin αvβ3. Herein, and three truncated derivatives functionalized with cysteine (1-4) were synthesized labeled the [99mTc][Tc(N)PNP43]-synthon ([PNP43 = (CH3)2P(CH2)2N(C2H4OCH3)(CH2)2P(CH3)2]) (99mTc1-4) as basis recognition. The pharmacological parameters all radiolabeled peptides...
Prostate cancer (PCa) has become the most common tumor among males in Europe and USA. Adoptive immunotherapy appears as a promising strategy to control advanced stages of disease by specific targeting tumor, particular through chimeric antigen receptor T (CAR-T) cell therapy. Despite advancements CAR-T technology treatment hematological malignancies, solid tumors still represent challenge. To overcome current limits, other cellular effectors than lymphocytes are under study possible...
Prostate cancer (PCa) is the second leading cause of malignancy-related mortality in males Western world. Although treatment like prostatectomy and radiotherapy for localized have good results, similar positive outcomes are not achieved metastatic PCa. Consequently, these aggressive forms PCa urgently need new methods treatment. We already described an efficient specific second-generation (2G) Chimeric Antigen Receptor (CAR) against Specific Membrane (PSMA), a glycoprotein overexpressed...
// Anastasia De Luca 1, * , Debora Carpanese 2, Maria Cristina Rapanotti 3 Tara Mayte Suarez Viguria Antonietta Forgione 4 Dante Rotili Chiara Fulci 1 Egidio Iorio 5 Luigi Quintieri 6 Sergio Chimenti 7 Bianchi Antonio Rosato 8 Anna Caccuri Department of Experimental Medicine and Surgery, University Tor Vergata, 00133 Rome, Italy 2 Oncology Gastroenterology, Padova, 35128 Laboratory Medicine, Drug Chemistry Technologies, "Sapienza" University, 00185 Cell Biology Neurosciences, Istituto...
Abstract The clinical translation of theranostic 177 Lu-radiopharmaceuticals based on inhibitors the prostate-specific membrane antigen (PSMA) has demonstrated positive responses in patients with advanced prostate cancer (PCa). However, challenges still remain, particularly regarding their pharmacokinetic and dosimetric properties. We developed a potential PSMA-immunotheranostic agent by conjugation single-chain variable fragment IgGD2B antibody (scFvD2B) to DOTA, obtain Lu-labelled better...
Abstract Background Many trials supported pembrolizumab as a first-line monotherapy to significantly improve overall survival (OS) in selected patients with previously untreated metastatic Non–Small Cell Lung Cancer (mNSCLC) and PD-L1 TPS of ≥50% without EGFR/ALK mutations. The aim this study was reveal the correlation between OS adverse events real-world settings after 42 months. Methods This retrospective observational involved 98 mNSCLC, ≥ 50%, no aberrations. Patients were treated (200...
The two anti-epidermal growth factor receptor monoclonal antibodies (mAbs) cetuximab and panitumumab are the pillars for treatment of EGFR-positive, KRAS wild-type metastatic colorectal cancers. However, stability data these mAbs generally missing or incomplete. Here, we report first time an orthogonal analysis (Erbitux®) (Vectibix®), either undiluted vial leftovers saline dilutions in polyolefin/polyamide infusion bags. All samples were stored at 2-8 °C protected from light, according to...
Preparation of injectable anticancer drugs in hospital pharmacies is a high-risk activity that requires proper risk assessment (RA) and quality assurance system (QAS) to ensure both decrease associated with chemotherapy compounding high the final product, especially terms its microbiological stability.At centralized unit (UFA) Italian Hospital IOV-IRCCS, quick deductive method was applied evaluate "added value" provided by each prescribed preparation, RA calculated applying formula...
Background: The [99mTc][Tc(N)(PNP)] system, where PNP is a bisphosphinoamine, an interesting platform for the development of tumor 'receptor-specific' agents. Here, we compared reactivity and impact three [Tc(N)(PNP)] frameworks on stability, receptor targeting properties, biodistribution, metabolism corresponding [99mTc][Tc(N)(PNP)]-tagged cRGDfK peptide to determine best performing agent select framework useful preparation [99mTc][Tc(N)(PNP)]-housing molecular Methods: pentapeptide was...
OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets V. Radchenko, J.W. Engle, C. Roy, J. Griswold, M.F. Nortier, E.R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M.E. Fassbender OP04 Comparison [68Ga]FSC(succ-RGD)3 and [68Ga]NODAGA-RGD for PET imaging αvβ3 integrin expression Chuangyan Zhai, Gerben Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo OP05 A new NPY-Y1R targeting peptide breast cancer Ait-Mohand Samia, Dumulon-Perreault...
Despite advances in the understanding of its molecular pathophysiology, prostate cancer remains largely incurable, highlighting need for novel therapies. We developed a chimeric antigen receptor (CAR) specific membrane (PSMA), glycoprotein that is overexpressed cancer, which expression involves neovasculature several tumor entities, thus envisaging an additional antiangiogenic effect. To optimize CAR design, we compared two CARs with signaling domains containing one or T cell costimulatory...